{
  "docId": "019de073-bb7b-734e-9815-c76c1fc3394d",
  "docSlug": "94fe5c987d3cc2789a772bd63dd63a40",
  "documentTitle": "Genprex | Investor Presentation Deck | 39 slides",
  "authorId": "genprex",
  "authorName": "Genprex",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 39,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide outlines a two-phase clinical trial structure and the specific patient progression timeline being measured.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-bb7b-734e-9815-c76c1fc3394d/16",
  "deckHref": "/decks/019de073-bb7b-734e-9815-c76c1fc3394d",
  "deckJsonHref": "/decks/019de073-bb7b-734e-9815-c76c1fc3394d.json",
  "deckAnchorHref": "/decks/019de073-bb7b-734e-9815-c76c1fc3394d#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.95,
        "x": 0.025,
        "y": 0.425
      },
      "kind": "diagram",
      "text": "Measuring Time From First Progression To Second Progression: Tagrisso Monotherapy vs. REQORSA + Tagrisso",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f56baea-afc3-49de-9cdf-278ed24e84c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.025,
        "y": 0.07
      },
      "kind": "list",
      "text": "GENERAL STUDY CHARACTERISTICS: FDA Fast Track Designation; Patients with advanced, EGFR mutant NSCLC whose disease progressed after Tagrisso; ~15 U.S. sites; ~92 patients (Phase 1: 9-18 patients, Phase 2: 74 patients); Interim analysis at 25 events; Expect to complete Phase 1 by year-end 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd88367a-5c36-476e-8d29-1e3560f2d45a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.45,
        "x": 0.525,
        "y": 0.155
      },
      "kind": "paragraph",
      "text": "REQORSA in combination with AstraZeneca's Tagrisso for NSCLC",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b687539-c97c-4cbb-99b3-f7bf4a341575",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.13,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Continuing Osimertinib (Tagrisso) Treatment After Progression Prolongs Survival Benefit in NSCLC. Targeted Oncology. https://www.targetedonc.com/view/continuing-osimertinib-treatment-after-progression-prolongs-survival. Accessed November 10, 2020.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad25d4f6-3a82-42d8-99e0-fb43afb50172",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.065,
        "w": 0.275,
        "x": 0.568,
        "y": 0.085
      },
      "kind": "title",
      "text": "Acclaim-1",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe7e1ec2-11a4-4264-8e5b-ff7e030ae83f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "0cc74827-bfd8-489f-92c3-2502b2f9d21a",
      "evidence": "The slide depicts a clinical trial progression timeline and study arm comparison.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 13,
      "beatId": "efbd2b1c-a70c-482c-b892-45fe876c5387",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "REQORSA MONOTHERAPY, REQORSA + TARCEVA COMBINATION, etc.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}